Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.
We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0237330 |
| _version_ | 1818933429719269376 |
|---|---|
| author | Mio Matsubara Yoichi Sakurada Atsushi Sugiyama Yoshiko Fukuda Ravi Parikh Kenji Kashiwagi |
| author_facet | Mio Matsubara Yoichi Sakurada Atsushi Sugiyama Yoshiko Fukuda Ravi Parikh Kenji Kashiwagi |
| author_sort | Mio Matsubara |
| collection | DOAJ |
| description | We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years. |
| first_indexed | 2024-12-20T04:48:15Z |
| format | Article |
| id | doaj.art-c709306a25b04bc1b89a46d26fdd2890 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T04:48:15Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c709306a25b04bc1b89a46d26fdd28902022-12-21T19:52:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01158e023733010.1371/journal.pone.0237330Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.Mio MatsubaraYoichi SakuradaAtsushi SugiyamaYoshiko FukudaRavi ParikhKenji KashiwagiWe investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.https://doi.org/10.1371/journal.pone.0237330 |
| spellingShingle | Mio Matsubara Yoichi Sakurada Atsushi Sugiyama Yoshiko Fukuda Ravi Parikh Kenji Kashiwagi Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. PLoS ONE |
| title | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. |
| title_full | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. |
| title_fullStr | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. |
| title_full_unstemmed | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. |
| title_short | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results. |
| title_sort | response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow eye condition 2 year results |
| url | https://doi.org/10.1371/journal.pone.0237330 |
| work_keys_str_mv | AT miomatsubara responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults AT yoichisakurada responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults AT atsushisugiyama responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults AT yoshikofukuda responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults AT raviparikh responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults AT kenjikashiwagi responsetophotodynamictherapycombinedwithintravitrealafliberceptforpolypoidalchoroidalvasculopathydependingonfelloweyecondition2yearresults |